Prevalence of Intestinal Parasitic Infections in Patients With Irritable Bowel Syndrome

April 14, 2023 updated by: Nada Mahmoud Ahmed, Sohag University

Prevalence of Intestinal Parasitic Infections in Irritable Bowel Syndrome Patients in Sohag, Egypt

Irritable bowel syndrome (IBS) is common medical disorder and represent a group of diseases of the gastrointestinal tract that is characterized by chronic abdominal pain , bloating , passage of mucus or straining with bowel movements, sense of incomplete evacuation after bowel movements or sense of urgency to move the bowels.Several parasites including Entamoeba. histolytica, Giardia spp., Blastocystis. hominis, and Trichinella spp. have been discussed as contributing factors to the development of IBS.

B. hominis is one of the most common human intestinal protozoa in both developing and developed countries. some studies have reported a significant association between the parasitic infections, especially Blastocystis, and IBS.Cryptosporidium has been reported in IBS patients, with the onset of gastrointestinal symptoms after an acute episode of cryptosporidiosis despite recovery and parasite clearance.Numerous studies have been conducted to evaluate the association between the parasitic infections and IBS.

Aim of the work:

To detect prevalence of intestinal parasitic infections in irritable bowel syndrome patients in sohag.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Sohag, Egypt, 093
        • Recruiting
        • faculty of medicine Sohag university
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

samples will be collected from outpatients complaining of symptoms of IBS fulfilling the Rome criteria , such as abdominal discomfort, diarrhea, and constipation, bloating with any age & sex groups from different locations (cities and village).

Description

Inclusion Criteria:

  • Patients complaining of symptoms of IBS, such as abdominal discomfort, diarrhea, and constipation, bloating with any age & sex groups

Exclusion Criteria:

  • Patients have celiac disease, gastrointestinal malignancies , inflammatory bowel disease , HIV , and those on immunosuppression and those who had been recently taking antibiotics within the previous four weeks and anti-parasitic drugs within the previous two weeks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
case
patients complaining of symptoms of IBS fulfilling the Rome criteria , such as abdominal discomfort, diarrhea, and constipation, bloating with any age & sex groups from different locations.
control
healthy individuals not suffering from IBS symptoms such as abdominal discomfort, diarrhea, and constipation, bloating.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To detect prevalence of intestinal parasitic infections in irritable bowel syndrome patients in sohag.
Time Frame: 16 weeks following the startpoint of the study.
will collect 200 stool samples : 100 samples will be collected from patients complaining of symptoms of IBS fulfilling the Rome criteria , such as abdominal discomfort, diarrhea, and constipation, bloating with any age & sex groups from different locations (cities and village) And 100 samples healthy controls.the samples will be examined for parasitological examination to detect prevalence of intestinal parasitic infections in irritable bowel syndrome patients.
16 weeks following the startpoint of the study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

May 1, 2023

Primary Completion (Anticipated)

November 30, 2023

Study Completion (Anticipated)

January 1, 2024

Study Registration Dates

First Submitted

April 12, 2023

First Submitted That Met QC Criteria

April 14, 2023

First Posted (Actual)

April 26, 2023

Study Record Updates

Last Update Posted (Actual)

April 26, 2023

Last Update Submitted That Met QC Criteria

April 14, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-23-04-23MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Irritable Bowel Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe